
Stem cell bank LifeCell raises ₹225 crore
The Hindu
The additional funds would enable LifeCell to make a foray into adjacent new categories such as fertility health and cell-based therapeutics.
Stem cell bank and reproductive genetic testing service provider LifeCell International Pvt. Ltd. said that OrbiMed Asia Partners IV has invested ₹225 crore in return for a minority stake.
“We received an equity infusion of ₹225 crore from leading healthcare investment firm OrbiMed Asia Partners IV. The existing founders will invest ₹30 crore,” said Mayur Abhaya, MD.
The additional funds would enable LifeCell to make a foray into adjacent new categories such as fertility health and cell-based therapeutics. Besides, it would also enable the company grow its diagnostic division and set up laboratories offering varied kinds of tests.

Insurance penetration and density are often misunderstood and do not reveal how many families are insured or whether they would be financially secure if the main earning member were to die. The real issue is not reach but adequacy, as households may have life insurance but not enough cover to replace lost income, leaving them financially vulnerable.












